Somewhat Critical Press Coverage Somewhat Unlikely to Impact Aegerion Pharmaceuticals (AEGR) Share Price

Press coverage about Aegerion Pharmaceuticals (NASDAQ:AEGR) has been trending somewhat negative on Thursday, Accern Sentiment reports. Accern identifies positive and negative press coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Aegerion Pharmaceuticals earned a news impact score of -0.02 on Accern’s scale. Accern also gave news stories about the biopharmaceutical company an impact score of 44.6259032875899 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.

Shares of Aegerion Pharmaceuticals (AEGR) traded up $0.10 on Thursday, reaching $1.97. 2,168,900 shares of the company’s stock were exchanged, compared to its average volume of 635,262. The stock has a market capitalization of $56.69, a PE ratio of -0.33 and a beta of 0.50. The company has a current ratio of 1.02, a quick ratio of 0.67 and a debt-to-equity ratio of -19.22. Aegerion Pharmaceuticals has a twelve month low of $1.23 and a twelve month high of $10.85.

COPYRIGHT VIOLATION WARNING: This piece of content was originally posted by Ticker Report and is the property of of Ticker Report. If you are viewing this piece of content on another website, it was stolen and republished in violation of international copyright and trademark laws. The correct version of this piece of content can be read at https://www.tickerreport.com/banking-finance/3125665/somewhat-critical-press-coverage-somewhat-unlikely-to-impact-aegerion-pharmaceuticals-aegr-share-price.html.

Aegerion Pharmaceuticals Company Profile

Aegerion Pharmaceuticals, Inc is a biopharmaceutical company engaged in the development and commercialization of therapies for patients with debilitating rare diseases. It operates through pharmaceuticals segment. Its products include lomitapide and metreleptin. Lomitapide is a small molecule microsomal triglyceride transfer protein (MTP) inhibitor.

Insider Buying and Selling by Quarter for Aegerion Pharmaceuticals (NASDAQ:AEGR)

Receive News & Ratings for Aegerion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aegerion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

How to Trade on Forex – 8 Steps for Beginners
How to Trade on Forex – 8 Steps for Beginners
Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


© 2006-2018 Ticker Report. Google+.